Market intelligence for the peptide supply chain
APIs ·

South Korea's HLB Pep wins $500,000 clinical API manufacturing contract

November 20, 2026 · TideMetrix Brief
TideMetrix TakeHLB Pep's latest clinical-stage manufacturing contract is equivalent to more than 13% of its 2025 revenue, highlighting the importance of individual drug development programmes to smaller API manufacturers.

South Korean peptide manufacturer HLB Pep has secured a KRW666 million (approximately $500,000) contract with Skinmed to develop and manufacture an active pharmaceutical ingredient (API) for Phase II clinical trials.

The agreement, signed on November 19 and disclosed in a regulatory filing on November 20, runs through September 30, 2028.

The contract value, excluding VAT, represents 13.42% of HLB Pep's reported 2025 revenue, with payments linked to progress under the agreement.

HLB Pep will supply the API through its own domestic manufacturing operations rather than subcontracting production.

The company did not disclose the identity of the molecule, the manufacturing location or anticipated production volumes. Contract value and duration may change as development progresses.

Sources

← Back to News